Ian Churcher

Company: Amphista Therapeutics

Job title: CSO

Seminars:

New Approaches to Degradation – Beyond the Usual Suspects 9:00 am

Amphista Therapeutics uses a completely novel range of mechanisms to degrade a wide range of disease-relevant proteins Mechanisms go beyond the usual E3 ligases utilised by most in the field and instead use other UPS proteins which offer new opportunities to expand the scope and utility of TPD strategies We will discuss how novel mechanisms…Read more

day: Day One